Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8706-8714

  Nowrousian, Mohammad R ^a   Brandhorst, Dieter ^a   Sammet, Christiane ^a   Kellert, Michaela ^a   Daniels, Rainer ^a   Schuett, Philipp ^a   Poser, Miriam ^a   Mueller, Siemke ^a   Ebeling, Peter ^a   Welt, Anja ^a   Bradwell, Arthur R ^b,c   Buttkereit, Ulrike ^a   Opalka, Bertram ^a   Flasshove, Michael ^a   Moritz, Thomas ^a   Seeber, Siegfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Binding Site Group Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; MONOCLONAL ANTIBODY; PARAPROTEIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; ELECTROPHORESIS; FEMALE; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELIABILITY; URINALYSIS; URINARY EXCRETION; URINE IMMUNOFIXATION ELECTROPHORESIS;

BENCE JONES PROTEIN; HUMANS; IMMUNOASSAY; IMMUNOELECTROPHORESIS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; SENSITIVITY AND SPECIFICITY;

EID: 29344446814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0486     Document Type: Article

References (24)

1. Bradwell AR, Carr-Smith HD, Mead GP, Drayson MT. Serum free light chain immunoassays and their clinical application. Clin Appl Immunol Rev 2002;3: 17-33.
2. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48:655-7.
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2.
4. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
5. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-8.
6. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348-54.
7. McLaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 1982;60:851-5.
8. Reid SD, Drayson MT, Mead GP, Augustson B, Roberts S, Bradwell AR. Serum free light chain assays for determining complete remission in multiple myeloma patients [abstract C-34]. Clin Chem 2004;50:A79.
9. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
10. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47:673-80.
11. Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum and early morning urine. Clin Lab 2000;46:53-5.
12. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489-91.
13. Marshall T, Williams KM. Electrophoretic analysis of Bence Jones proteinuria. Electrophoresis 1999;20: 1307-24.
14. Beetham R. Detection of Bence-Jones protein in practice. Ann Clin Biochem 2000;37:563-70.
15. Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338-46.
16. Pascali E. Bence Jones proteins identified by immunofixation electrophoresis of concentrated urine. Clin Chem 1994;40:945-6.
17. Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis. Clin Chem 1994; 40:1869-78.
18. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46:1230-8.
19. Harrison HH. The "ladder light chain" or "pseudo- oligoclonal" pattern in urinary immunofixation electrophoresis (IFE) studies: a distinctive IFE pattern and an explanatory hypothesis relating it to free polyclonal light chains. Clin Chem 1991;37:1559-64.
20. Hess PP, Mastropaolo W, Thompson GD, Levinson SS. Interference of polyclonal free light chains with identification of Bence Jones proteins. Clin Chem 1993;39:1734-8.
21. MacNamara EM, Aguzzi F, Petrini C, et al. Restricted electrophoretic heterogeneity of immunoglobulin light chains in urine: a cause for confusion with Bence Jones protein. Clin Chem 1991;37:1570-4.
22. Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004;75: 246-8.
23. Cooper EH, Forbes MA, Crockson RA, MacLennan IC. Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J Clin Pathol 1984;37:852-8.
24. Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-7.